BioNTech Holds €17.2B Cash While Launching Six New Phase 3 Trials
BioNTech outlined a 2026 plan to launch six new Phase 3 oncology trials, adding to its 25 ongoing Phase 2 and 3 studies across immunomodulators, antibody-drug conjugates and mRNA therapies. The company held €17.2 billion in cash as of December 2025, funding at least 17 late-stage data readouts through 2030.
1. Pipeline Expansion Plan
BioNTech unveiled plans to initiate six additional Phase 3 oncology trials in 2026, supplementing over 25 ongoing Phase 2 and 3 studies. These trials span key modalities including immunomodulators, antibody-drug conjugates and mRNA-based cancer immunotherapies, reflecting a strategic focus on diversified treatment platforms.
2. Financial Preparedness for Late-Stage Trials
As of December 2025, BioNTech reported €17.2 billion in cash reserves, positioning it to fund at least 17 late-stage data readouts through 2030 without significant dilution. This robust balance sheet underpins the company’s accelerated clinical development timeline and support for multiple simultaneous registrational programs.